News
Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers
Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular...
Study Demonstrates Elucid’s Ability to Estimate RNA Expression from Non-Invasive Cardiovascular Imaging
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular...
Study Confirms Elucid’s AI Software Accurately Estimates Lesion-Specific Ischemia Compared to Standard of Care
BOSTON--(BUSINESS WIRE)--Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced today the publication of new clinical data in the International Journal of Cardiology. The study, entitled “Coronary plaque...